WuXi
-
Bristol-Myers Squibb, WuXi PharmaTech collaborate on new testing facility
Bristol-Myers Squibb Company and WuXi PharmaTech announced that they have entered a strategic partnership to conduct stability studies of smallmolecule new chemical entities to support global marketing applications. Under the agreement, WuXi will bu…
WuXi | 01 May 2011
-
Bristol-Myers Squibb and WuXi PharmaTech announce collaboration for new testing facility
Bristol-Myers Squibb Company and WuXi PharmaTech announced that they have entered a strategic partnership to conduct stability studies of small-molecule new chemical entities to support global marketing applications. Under the agreement, WuXi wil…
WuXi | 08 March 2011
-
Charles River to Merge with Wuxi
Charles River Laboratories International and WuXi PharmaTech (Cayman) have signed an agreement under which the companies will combine in a cash and stock transaction valued at approximately US$1.6 billion. The combined company, which will retain …
WuXi | 21 May 2010
-
Qiagen and WuXi AppTec Partner for Biomarker Development in China
Qiagen Asia Pacific and WuXi AppTec have announced a partnership to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases. The former will provid…
WuXi | 13 January 2010
-
WuXi PharmaTech to Focus its US Operations on Laboratory Testing Services
WuXi PharmaTech has announced that it will dedicate its Philadelphia facility to the company's biologics testing, cell banking and cell therapy services. As of December 31, 2008, WuXi will discontinue its US biologics manufacturing operations. In…
WuXi | 08 December 2008
-
WuXi PharmaTech reports 9% increase in gross profit
WuXi PharmaTech (Cayman) has reported in its unaudited financial results for the third quarter ended September 30, 2008 that its net revenue increased 98% year-over-year to $67.5 million. The manufacturing services segment focuses on advanced int…
WuXi | 24 November 2008
-
Covance and WuXi PharmaTech to provide preclinical services in China
WuXi PharmaTech and Covance Inc. have announced entering into a Memorandum of Understanding to create a 50-50 joint venture which will provide world-class preclinical contract research services in China. Operations of the proposed joint venture w…
WuXi | 25 July 2008
-
WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc
WuXi PharmaTech, China's premier provider of pharmaceutical R&D outsourcing services, has signed a definitive agreement to acquire US-based AppTec Laboratory Services, Inc. The acquisition of AppTec allows WuXi PharmaTech to immediately obtain bio…
WuXi | 07 January 2008
-
WuXi PharmaTech Ranked 28 in Deloitte Technology Fast 50 China
WuXi PharmaTech, China’s premier provider of pharmaceutical R&D outsourcing services said it has been ranked 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. The Fast 50 C…
WuXi | 01 November 2007
-
WuXi PharmaTech CEO In CrossFire Beilstein Database Advisory Board
WuXi PharmaTech, China's premier provider of pharmaceutical R&D outsourcing services announced that its Chairman and CEO has been appointed to a newly established advisory board of Elsevier Information Systems GmbH. Elsevier Information Systems G…
WuXi | 27 August 2007
